![]() ![]() The study involved 22 patients who received olaparib along with a low dose of temozolomide, a chemotherapy drug. So our idea is to use precision medicine to define a subset of women who would benefit from a PARP inhibitor.” “Chemotherapy has been tried with only a very modest effect on improving survival. Schwartz, MD, deputy director of the HICCC, chief of Columbia's Division of Hematology and Oncology, and a co-investigator in the clinical trial. In the metastatic setting, it is incurable, and even when resected, recurrences are high,” says Gary K. “Uterine leiomyosarcoma is a deadly disease. ![]() The trial aimed to test a novel therapy for uterine leiomyosarcoma called olaparib, a PARP inhibitor originally developed for individuals with BRCA1 or BRCA2 mutations. Only about 10 percent of patients respond, and even then, progression-free survival typically lasts a few months at the most. Second-line treatment options for uterine leiomyosarcoma provide limited benefit and are usually quite toxic. ![]() Top: patient who experienced reduction in size of a large pelvic mass Bottom: a patient who had significant shrinkage of a scalp lesion among other sites of metastatic disease. Shown here: Representative images from a subset of patients, with 2 prior lines of treatment, achieving partial response on the study. The drug combination resulted in durable responses with a progression-free survival of almost 7 months in a group of patients who progressed after front-line chemotherapy. The research, presented at the annual meeting of the American Society of Clinical Oncology held online June 4-8, was led by a team at the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork-Presbyterian/ Columbia University Irving Medcial Center. Results of a new phase 2 clinical trial demonstrate the potential of targeted therapy in combination with chemotherapy to treat patients with uterine leiomyosarcoma. Most patients show no symptoms before diagnosis, but if the cancer has spread to other parts of the body, the prognosis is extremely poor. The malignant smooth muscle tumor arises in the uterus and is frequently detected during a routine gynecological surgery. He joined the faculty of the University of Arizona as a senior professor in 1988.A rare, aggressive form of cancer called uterine leiomyosarcoma, which affects roughly 2,500 women every year in the U.S., is often discovered entirely by accident. Schwartz later became a tenured professor of psychology and psychiatry at Yale University, directed the Yale Psychophysiology Center, and co-directed the Yale Behavioral Medicine Clinic. He was an assistant professor at Harvard for five years. Schwartz also served as Chairman of Eternea, an organization whose mission is to foster the integration of science and spirituality for personal and global transformation.Īfter receiving his master’s degree from Harvard in clinical psychology, he earned a PhD there in psychophysiology. He collaborated with Canyon Ranch on biofield science and energy healing research and served as the Corporate Director of Development of Energy Healing. Schwartz was the founding president of the Academy for Advances in Postmaterial Sciences. This funding created the Center for Frontier Medicine in Biofield Science at the University of Arizona that he directed for four years. Schwartz received a two million-dollar award from the National Center on Complementary and Alternative Medicine of the National Institutes of Health. ![]()
0 Comments
Leave a Reply. |